Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ernexa Therapeutics (ERNA) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to -$0.15.

  • Ernexa Therapeutics' EPS (Basic) rose 9979.65% to -$0.15 in Q3 2025 from the same period last year, while for Sep 2025 it was $103.28, marking a year-over-year increase of 21298.55%. This contributed to the annual value of -$3.26 for FY2024, which is 1999.05% up from last year.
  • Latest data reveals that Ernexa Therapeutics reported EPS (Basic) of -$0.15 as of Q3 2025, which was up 9979.65% from -$0.61 recorded in Q2 2025.
  • In the past 5 years, Ernexa Therapeutics' EPS (Basic) ranged from a high of -$0.15 in Q1 2025 and a low of -$73.7 during Q3 2024
  • For the 5-year period, Ernexa Therapeutics' EPS (Basic) averaged around -$8.18, with its median value being -$1.16 (2023).
  • Per our database at Business Quant, Ernexa Therapeutics' EPS (Basic) plummeted by 4040237.73% in 2021 and then surged by 9979.65% in 2025.
  • Ernexa Therapeutics' EPS (Basic) (Quarter) stood at -$34.03 in 2021, then surged by 95.67% to -$1.47 in 2022, then grew by 21.34% to -$1.16 in 2023, then surged by 63.55% to -$0.42 in 2024, then soared by 64.5% to -$0.15 in 2025.
  • Its EPS (Basic) stands at -$0.15 for Q3 2025, versus -$0.61 for Q2 2025 and -$0.15 for Q1 2025.